A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blas
about
Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?Myelodysplasia and the acute myeloid leukaemias.P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.The role of purine analogue combinations in the management of acute leukemias.The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients.Role of fludarabine in hematological malignancies.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Treatment of refractory and relapsed acute myelogenous leukemia.Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.Purine nucleoside analogues in the treatment of myleoid leukemias.Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.Biology and management of relapsed acute myeloid leukaemia.Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia.Guidelines on the management of acute myeloid leukaemia in adults.Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemiaThe clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction.Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.Update on optimal management of acute myeloid leukemiaRetrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemiaCyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapse.Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome.Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
P2860
Q26860830-B167C081-A80A-46CB-BD6F-EDADE87A730AQ33345617-154C19AC-7CA9-4A6E-BFE1-BEBA2491339BQ34142289-DB09436E-33A7-4F72-A219-8094CEFD6FABQ34154708-5883F57D-B910-4B90-AB1E-95EF8067ECE3Q34469145-8F7DA6BA-35C7-4F15-A595-F79446037DCEQ34569051-564FB84D-B7B8-4190-B4B7-1CCD83B2E5DEQ34571439-6CF86EE2-918E-4237-ACA7-1999BFA5D44CQ34630777-7C29D31C-EDF3-46DE-BB43-69AEBDA632AAQ34734034-DF800B17-ED3F-420C-951F-C7C647C9D744Q34996869-6ECF9196-A507-4B92-8A2B-CD0E75515811Q35104351-EE8FE033-3659-4FF3-9CEC-653A65F61785Q35278018-513E3BCD-F5C6-4BCF-A09D-7E19A24BF448Q36085026-9B1AC0BF-58E2-451E-B9B6-290B414AB724Q36152664-ECAAA11D-AB57-466E-8349-84D5E2C205F8Q36529403-09C89274-34DD-427D-BAFF-5A72FB50667AQ36630107-7722C4CB-5134-45AC-BD36-00971D43D5F7Q36761725-31F2050B-0981-44AA-88BD-7F3D0EBB0109Q36806921-14E9406C-9C9E-4949-956D-C27EB6647BA4Q37232078-47917E17-C98A-4BC0-9B15-468A7F783261Q38293997-E4D3FEFB-8F2A-4005-865B-FE99D5590073Q38917137-6E40AA68-72A7-431D-9797-0EF9ACBD83BDQ39296422-78A3C94F-CEAE-470D-BA8F-960E0F0199CBQ39342733-DA7C25F7-C65F-4C6B-AD32-419F1F575510Q40426733-1AEE6BAB-9707-44A5-8A81-001404059DC4Q40535533-37CF710A-8FE5-43C9-94C5-820A3849C4CFQ40554967-6388CE41-EF5F-4F7E-9F46-DF278CE1FB47Q40780156-8DA8A191-1884-4AF6-8BD7-BAFD6203509AQ41894404-14ED4C3E-0EA7-4003-A27C-4BCB9A73A51FQ41961502-49CE8231-2D45-4749-833F-4BC386FBE99BQ42538576-1DA58FBF-9E54-4B02-9AF5-1981A589721FQ42949481-D7A58CAD-7754-46C1-BA6B-EFC6DD4FD083Q44033083-799FB780-7B9C-4120-AC6E-046F0531E4B9Q44557341-EAB8D8A0-70AE-4B8C-B4E4-1A05FE4454D4Q44689211-8B2498B3-CD92-4EDE-B22A-228AAE2CCE4AQ44693239-2FF6CC6C-0212-4DDA-A581-DACBC1AD3884Q44763721-EC5524A3-F4C5-45DD-A27D-EAA32071448EQ47232101-CCEC7CEB-B6EA-449C-B492-3CE3E3B1A85CQ49912628-9777B16B-E63B-4A82-847E-5C9DCE2DEB66Q50923400-6840C325-B694-4DC7-A211-0979728C0C4DQ53298864-DF11B7EA-0667-4914-BA3E-1B98877DDEC2
P2860
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blas
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@ast
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@en
type
label
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@ast
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@en
prefLabel
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@ast
A multicentre, open, non-compa ...... ry anaemia with excess of blas
@en
P2093
P2860
P1476
A multicentre, open, non-compa ...... ss of blasts in transformation
@en
P2093
A Duncombe
G E Turner
M Hutchinson
M J MacKie
P2860
P304
P356
10.1046/J.1365-2141.2001.02551.X
P407
P50
P577
2001-01-01T00:00:00Z